MA54289A - Analogues deutérés d'acétyl-leucine - Google Patents
Analogues deutérés d'acétyl-leucineInfo
- Publication number
- MA54289A MA54289A MA054289A MA54289A MA54289A MA 54289 A MA54289 A MA 54289A MA 054289 A MA054289 A MA 054289A MA 54289 A MA54289 A MA 54289A MA 54289 A MA54289 A MA 54289A
- Authority
- MA
- Morocco
- Prior art keywords
- leucine
- acetyl
- deuterated analogs
- deuterated
- analogs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862776297P | 2018-12-06 | 2018-12-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54289A true MA54289A (fr) | 2021-10-06 |
Family
ID=68887086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054289A MA54289A (fr) | 2018-12-06 | 2019-12-06 | Analogues deutérés d'acétyl-leucine |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12145899B2 (fr) |
| EP (1) | EP3886986A1 (fr) |
| JP (3) | JP7471298B2 (fr) |
| KR (2) | KR102765448B1 (fr) |
| CN (2) | CN120157593A (fr) |
| AU (1) | AU2019391434B2 (fr) |
| BR (1) | BR112021010923A2 (fr) |
| IL (2) | IL283673B2 (fr) |
| MA (1) | MA54289A (fr) |
| MX (2) | MX2021006559A (fr) |
| SA (1) | SA521422185B1 (fr) |
| SG (1) | SG11202106009TA (fr) |
| WO (1) | WO2020115715A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201709459D0 (en) | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
| CN120157593A (zh) | 2018-12-06 | 2025-06-17 | 内在生物技术有限公司 | 乙酰基-亮氨酸的氘代类似物 |
| MD3989962T2 (ro) | 2019-06-28 | 2025-12-31 | Intrabio Ltd Gb | Terapie combinată cu acetil-leucină și miglustat pentru tratamentul unei boli de depozitare lizozomală |
| WO2021144720A1 (fr) | 2020-01-13 | 2021-07-22 | Intrabio Ltd | Traitement de maladies neurodégénératives tardives chez des porteurs de mutations hétérozygotes du gène npc1 |
| WO2022264037A1 (fr) * | 2021-06-14 | 2022-12-22 | Intrabio Ltd. | Dérivés d'acides aminés à chaîne ramifiée pour traiter une maladie |
| WO2025166100A1 (fr) | 2024-02-02 | 2025-08-07 | SynGAP Research Fund | Compositions et méthodes de traitement de troubles neurodéveloppementaux |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100477070B1 (ko) * | 1994-03-25 | 2006-04-21 | 이소테크니카 인코포레이티드 | 중수소화작용에의한의약품의효능강화법 |
| US20060063827A1 (en) | 2004-09-23 | 2006-03-23 | Yu Ruey J | Systemic administration of therapeutic amino acids and N-acetylamino acids |
| US20050026823A1 (en) * | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
| CN103188933A (zh) * | 2010-10-26 | 2013-07-03 | 泰华制药工业有限公司 | 富集氘的雷沙吉兰 |
| JP6704252B2 (ja) | 2013-02-05 | 2020-06-03 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーTeva Pharmaceuticals International GmbH | 位置特異的非対称重水素富化カテコールアミン誘導体および前記化合物を含有する医薬 |
| PT3445351T (pt) * | 2016-04-19 | 2024-11-14 | Intrabio Ltd | Acetil-leucina ou um sal farmaceuticamente aceitável seu derivado para melhoria da mobilidade |
| PT3482754T (pt) * | 2016-08-11 | 2021-02-03 | Intrabio Ltd | Composições farmacêuticas e utilizações contra os distúrbios de armazenamento lisossómico |
| TN2019000033A1 (fr) | 2016-08-11 | 2020-07-15 | Intrabio Ltd | Agents thérapeutiques pour maladies neurodégénératives |
| PT3600276T (pt) | 2017-03-28 | 2023-07-11 | Intrabio Ltd | Beta-histina, ou um seu sal farmaceuticamente aceitável, e um inibidor da monoamina oxidase, para utilização no tratamento ou prevenção de um ou mais sintomas de vertigem num indivíduo |
| GB201709459D0 (en) * | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
| EP3697406A1 (fr) | 2017-10-18 | 2020-08-26 | IntraBio Ltd | Agents thérapeutiques pour mobilité et fonction cognitive améliorées et pour le traitement de maladies neurodégénératives et de troubles de stockage lysosomal |
| RS65663B1 (sr) | 2018-02-15 | 2024-07-31 | Intrabio Ltd | Acetil leucin za upotrebu u lečenju sindroma nemirnih nogu |
| CN120157593A (zh) * | 2018-12-06 | 2025-06-17 | 内在生物技术有限公司 | 乙酰基-亮氨酸的氘代类似物 |
| CN109448569A (zh) * | 2018-12-17 | 2019-03-08 | 武汉华星光电半导体显示技术有限公司 | 显示面板 |
| CN119097618A (zh) | 2019-03-02 | 2024-12-10 | 内在生物技术有限公司 | 用于治疗疾病的亮氨酸、乙酰基亮氨酸和相关类似物 |
| MD3989962T2 (ro) * | 2019-06-28 | 2025-12-31 | Intrabio Ltd Gb | Terapie combinată cu acetil-leucină și miglustat pentru tratamentul unei boli de depozitare lizozomală |
| WO2021144720A1 (fr) * | 2020-01-13 | 2021-07-22 | Intrabio Ltd | Traitement de maladies neurodégénératives tardives chez des porteurs de mutations hétérozygotes du gène npc1 |
| KR20230015433A (ko) * | 2020-05-22 | 2023-01-31 | 인트라바이오 리미티드 | 운동실조를 치료하기 위한 아세틸 류신과 4-아미노피리딘 또는 아세타졸아미드의 조합물 |
-
2019
- 2019-12-06 CN CN202510303881.2A patent/CN120157593A/zh active Pending
- 2019-12-06 SG SG11202106009TA patent/SG11202106009TA/en unknown
- 2019-12-06 IL IL283673A patent/IL283673B2/en unknown
- 2019-12-06 WO PCT/IB2019/060525 patent/WO2020115715A1/fr not_active Ceased
- 2019-12-06 KR KR1020217019782A patent/KR102765448B1/ko active Active
- 2019-12-06 IL IL319687A patent/IL319687A/en unknown
- 2019-12-06 MA MA054289A patent/MA54289A/fr unknown
- 2019-12-06 CN CN201980090399.8A patent/CN113348018B/zh active Active
- 2019-12-06 KR KR1020257003486A patent/KR20250022899A/ko active Pending
- 2019-12-06 AU AU2019391434A patent/AU2019391434B2/en active Active
- 2019-12-06 JP JP2021531964A patent/JP7471298B2/ja active Active
- 2019-12-06 MX MX2021006559A patent/MX2021006559A/es unknown
- 2019-12-06 US US17/311,240 patent/US12145899B2/en active Active
- 2019-12-06 EP EP19820881.1A patent/EP3886986A1/fr active Pending
- 2019-12-06 BR BR112021010923-4A patent/BR112021010923A2/pt unknown
-
2021
- 2021-06-03 MX MX2024005670A patent/MX2024005670A/es unknown
- 2021-06-06 SA SA521422185A patent/SA521422185B1/ar unknown
-
2024
- 2024-04-09 JP JP2024062686A patent/JP2024095769A/ja not_active Withdrawn
- 2024-10-21 US US18/921,779 patent/US20250129011A1/en active Pending
-
2025
- 2025-10-23 JP JP2025178241A patent/JP2026016521A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250129011A1 (en) | 2025-04-24 |
| IL283673B2 (en) | 2025-08-01 |
| MX2021006559A (es) | 2021-08-16 |
| CN120157593A (zh) | 2025-06-17 |
| JP7471298B2 (ja) | 2024-04-19 |
| JP2022514823A (ja) | 2022-02-16 |
| JP2024095769A (ja) | 2024-07-10 |
| BR112021010923A2 (pt) | 2021-08-24 |
| MX2024005670A (es) | 2024-05-30 |
| SA521422185B1 (ar) | 2024-04-24 |
| CA3122223A1 (fr) | 2020-06-11 |
| US20220024858A1 (en) | 2022-01-27 |
| KR20210111757A (ko) | 2021-09-13 |
| WO2020115715A1 (fr) | 2020-06-11 |
| JP2026016521A (ja) | 2026-02-03 |
| IL283673B1 (en) | 2025-04-01 |
| AU2019391434B2 (en) | 2025-01-09 |
| KR20250022899A (ko) | 2025-02-17 |
| IL283673A (en) | 2021-07-29 |
| SG11202106009TA (en) | 2021-07-29 |
| CN113348018A (zh) | 2021-09-03 |
| CN113348018B (zh) | 2025-04-01 |
| IL319687A (en) | 2025-05-01 |
| AU2019391434A1 (en) | 2021-07-08 |
| EP3886986A1 (fr) | 2021-10-06 |
| US12145899B2 (en) | 2024-11-19 |
| KR102765448B1 (ko) | 2025-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3870593A4 (fr) | Analogues nucléotidiques | |
| IL283385A (en) | Modified gip peptide analogues | |
| MA46180A (fr) | Analogues de l'amyline | |
| EP3328827A4 (fr) | Promédicaments d'analogues de glutamine | |
| EP3820473A4 (fr) | Synthèse enzymatique d'analogues de nucléosides de type 4'-éthynyle | |
| EP3860449A4 (fr) | Agencement d'électrodes | |
| UA42295S (uk) | Комп'ютер | |
| IL283673A (en) | Deuterated analogs of acetyl-leucine | |
| MA53085A (fr) | Thiophènecarboxamides substitués et analogues comme agents antibactériens | |
| EP3846791A4 (fr) | Analogues d'illudine, utilisations associées et leurs procédés de synthèse | |
| MA50047A (fr) | Administration orale d'analogues peptidiques de glp-1 | |
| EP3325487A4 (fr) | Préparation pour analogues d'anticholinergiques à potentiel modéré | |
| EP3347334A4 (fr) | Déshydrohalogénation d'hydrochlorofluorocarbones | |
| MX383647B (es) | Análogos deuterados de etifoxina, sus derivados y usos de estos. | |
| EP3752149A4 (fr) | Analogues de quinolone, sels correspondants, compositions et procédé d'utilisation | |
| EP3472176A4 (fr) | L'utilité de (+) épicatéchine et de leurs analogues | |
| EP3627775A4 (fr) | Synchronisation d'itinéraire | |
| PL3898602T3 (pl) | Synteza 3-metylo-1,2,4-tiadiazolo-5-karbohydrazydu lub jego metylo-d3 deuterowanej postaci | |
| EP3920962A4 (fr) | Purification d'analogues de glp-1 | |
| SI3512495T1 (sl) | Formulacije prostaciklinskih analogov | |
| EP3891220A4 (fr) | Mélanges d'élastomères thermoplastiques fluorés | |
| DK3886813T3 (da) | Farmaceutiske formuleringer af cyclosporinanaloger | |
| EP4426673A4 (fr) | Analogues de la pentamidine | |
| ZA202006370B (en) | Deuterated analogs of elacridar | |
| EP3906225C0 (fr) | Analogues de pantothénamide |